All In Biotech

Free tool

FAERS Monitor: Enstilar

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 207589 or its brand name (Enstilar, Betamethasone Dipropionate, Calcipotriene). Reports on generic versions are filed under their own applications.

Reports

1,902

Serious

1,359

71% of reports

Hospitalization

569

Death reported

95

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • psoriasis398
  • drug ineffective181
  • diarrhoea138
  • pruritus132
  • pain111
  • headache109
  • fatigue92
  • arthralgia90
  • psoriatic arthropathy90
  • rash86
  • nausea82
  • dyspnoea77
  • erythema73
  • nasopharyngitis70
  • malaise63

Reports by year received

View as table
YearReports
201011
201216
20141
20154
201661
2017100
2018160
2019239
2020279
2021219
2022198
2023272
2024149
2025116
202677

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,257 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
psoriasisSignal39833.831.012,675
psoriatic arthropathySignal9024.620.12,011
nasopharyngitisSignal704.23.3169
erythemaSignal733.93.1158
pruritusSignal1323.83.2274
arthralgiaSignal902.42.073
diarrhoeaSignal1382.42.0111
rashSignal862.21.855
pain1112.01.756
headache1091.91.649
malaise631.61.213
drug ineffective1811.51.334
dyspnoea771.51.213
fatigue921.31.17
nausea821.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.